Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers

Zhang Xinqi; Liu Shujun; Liang Yunyan; Liu Xinduo; Wang Daishu

doi:10.1007/BF02934053

Your Location：

Home >

Browse articles >

Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers

Updated：2021-08-27

- Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers
- Chinese Journal of Integrative Medicine Vol. 4, Issue 3, Pages: 175-177(1998)
- Affiliations：
  
  1. The School of Oncology, Beijing Medical University,Beijing
  2. The First Hospital, Beijing Medical University,Beijing
- Author bio：
- Funds：
- DOI：10.1007/BF02934053
  CLC：
- Published：1998，
Scan for full text
Zhang, X., Liu, S., Liang, Y. et al. Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers., CJIM 4, 175–177 (1998). https://doi.org/10.1007/BF02934053

Zhang Xinqi, Liu Shujun, Liang Yunyan, et al. Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers. [J]. Chinese Journal of Integrative Medicine 4(3):175-177(1998)
Zhang, X., Liu, S., Liang, Y. et al. Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers., CJIM 4, 175–177 (1998). https://doi.org/10.1007/BF02934053 DOI：

Zhang Xinqi, Liu Shujun, Liang Yunyan, et al. Bailong tablet and chemotherapy in the treatment of moderate and advanced cancersand chemotherapy in the treatment of moderate and advanced cancers. [J]. Chinese Journal of Integrative Medicine 4(3):175-177(1998) DOI： 10.1007/BF02934053.

摘要

Objective: To determine the effectiveness of Bailong Tablet and chemotherapy on treatment of moderate and advanced cancers.Methods: The patients were divided randomly into two groups. The treated group (n= 41) was treated with chemotherapy plus Bailong Tablet; and the control group (n= 22) treated with chemotherapy alone. Treatment effectiveness was measured with Karnofsky scores.Results: Karnofsky performance status in the treated group before and after treatment was 66.0 ± 8.7 and 68.0 ± 5.9 respectively

that in the control group was 67. 0 ± 6.8 and 53. 0 ± 7.3 respectively. The completion rate of chemotherapy in the treated group (92.6%

38/41) was higher than that in control (77.2%

17/22

P < 0.05). The side-effects caused by chemotherapy in the treated group were lower than that in the control group (P < 0.05). CD3 +

CD4 + and CD4 + /CD8 + ratio were higher in the treated group.Conclusion: Bailong Tablet can enhance the therapeutic effect and reduce the side-effects of chemotherapy. One possible mechanism is the modulation of cellular immune function.

Abstract

that in the control group was 67. 0 ± 6.8 and 53. 0 ± 7.3 respectively. The completion rate of chemotherapy in the treated group (92.6%

38/41) was higher than that in control (77.2%

17/22

P < 0.05). The side-effects caused by chemotherapy in the treated group were lower than that in the control group (P < 0.05). CD3 +

关键词

malignant tumorchemotherapyBailong TabletT lymphocyte subset

Keywords

malignant tumorchemotherapyBailong TabletT lymphocyte subset

references

1990: 2 1–14, 4 14–50, 6 1–3, 15.

1, 1995:485–507.

A 1997; 16(4):246.

1994; 14 :302.

FULL TEXT LINK

More>

Views

369

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical and experimental study on Fuzheng Baozhen Decoction ( ) in enhancing effect of radio- and chemotherapy for malignant tumors) in enhancing effect of radio- and chemotherapy for malignant tumors

Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology

Related Author

No data

Related Institution

Xiangya Hospital, Hunan Medical University

Institute of Integrated Traditional Chinese and Western Medicine, Hunan Medical University

Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine

Department of Integrated Medicine, Shanghai Chest Hospital

Department of Oncology, Shanghai Punan Hospital of Pudong New District

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰